These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 26372797)

  • 41. Exploring novel perspectives on eosinophilic inflammation in severe asthma.
    Candia C; Ambrosino P; D'Anna SE; Motta A; Maniscalco M
    Biomark Med; 2024; 18(8):357-361. PubMed ID: 38623926
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma.
    Carr WW; McDonald M; Meizlik P
    Allergy Asthma Proc; 2019 Jul; 40(4):240-249. PubMed ID: 31262379
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
    Bakakos A; Rovina N; Bakakos P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benralizumab as a potential treatment of asthma.
    Antoniu SA
    Expert Opin Biol Ther; 2017 Jul; 17(7):895-900. PubMed ID: 28406319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?
    Varricchi G; Senna G; Loffredo S; Bagnasco D; Ferrando M; Canonica GW
    Front Immunol; 2017; 8():242. PubMed ID: 28344579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.
    Wechsler ME; Peters SP; Hill TD; Ariely R; DePietro MR; Driessen MT; Terasawa EL; Thomason DR; Panettieri RA
    Chest; 2021 May; 159(5):1734-1746. PubMed ID: 33333058
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis.
    He LL; Zhang L; Jiang L; Xu F; Fei DS
    Int Immunopharmacol; 2018 Nov; 64():223-231. PubMed ID: 30199847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reslizumab in the management of poorly controlled asthma: the data so far.
    Maselli DJ; Velez MI; Rogers L
    J Asthma Allergy; 2016; 9():155-62. PubMed ID: 27621657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?
    Katsoulis K; Kipourou M; Loukides S
    Expert Opin Biol Ther; 2022 Mar; 22(3):377-384. PubMed ID: 34328380
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.
    Pelaia C; Calabrese C; Vatrella A; Busceti MT; Garofalo E; Lombardo N; Terracciano R; Pelaia G
    Biomed Res Int; 2018; 2018():4839230. PubMed ID: 29862274
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mepolizumab-based therapy in asthma: an update.
    Walsh GM
    Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 53. IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.
    Luo J; Chen W; Liu W; Jiang S; Ye Y; Shrimanker R; Hynes G; Klenerman P; Pavord ID; Xue L
    Mucosal Immunol; 2024 Aug; 17(4):524-536. PubMed ID: 38493955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients with Severe Eosinophilic Asthma.
    Bateman ED; Djukanović R; Castro M; Canvin J; Germinaro M; Noble R; Garin M; Buhl R
    Am J Respir Crit Care Med; 2019 Feb; 199(4):489-495. PubMed ID: 30346831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.
    Ramonell RP; Iftikhar IH
    Lung; 2020 Feb; 198(1):95-103. PubMed ID: 31894410
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis.
    Yan K; Balijepalli C; Sharma R; Barakat S; Sun SX; Falcao S; Druyts E; FitzGerald JM
    Immunotherapy; 2019 Dec; 11(17):1491-1505. PubMed ID: 31686556
    [No Abstract]   [Full Text] [Related]  

  • 58. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma - First Initiators and Switchers.
    Hashimoto S; Kroes JA; Eger KA; Mau Asam PF; Hofstee HB; Bendien SA; Braunstahl GJ; Broeders MEAC; Imming LM; Langeveld B; Maitland-van der Zee AH; Oud KTM; Patberg KW; Smeenk FWJM; Romme EAPM; van Bezouw MJ; van de Ven MJ; van Veen A; van Velzen E; van Veen IHPAA; Weersink EJM; Ten Brinke A; Sont JK; Bel EH;
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2099-2108.e6. PubMed ID: 35487369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma.
    Lam J; Hay JW; Salcedo J; Kenyon NJ
    J Asthma; 2019 Aug; 56(8):872-881. PubMed ID: 30003833
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.